Guanylate cyclase C (GUCY2C) belongs to the receptor guanylate cyclase family and serves as the intestinal receptor for bacterial heat-stable enterotoxin, hence also known as the heat-stable enterotoxin receptor. The human GUCY2C gene is located on chromosome 12q12, encoding a type I transmembrane protein with a molecular weight of approximately 120 kDa. The GUCY2C protein structure consists of five main components: an extracellular N-terminal receptor-binding domain (comprising 40% of the protein) that binds specific ligands; a hydrophobic transmembrane domain that transmits extracellular signals intracellularly; a cytoplasmic kinase homology domain that relays signals from the ligand-bound receptor to the catalytic domain; a catalytic domain; and a carboxyl terminus. Ligands of GUCY2C include guanylin, uroguanylin, and bacterial heat-stable enterotoxin, which contain abundant cysteine residues and disulfide bonds in their peptide chains—essential for their biological functions. FITC-labeled GUCY2C Fc chimera protein can be used for quantitative detection of GUCY2C expression levels and binding activity, providing a technical tool for colorectal cancer research.
Activated by guanylin, uroguanylin, and heat-stable enterotoxin, GUCY2C regulates the dynamic balance of intestinal water and electrolytes, as well as epithelial cell transformation and proliferation. Extensive studies indicate that GUCY2C activation stimulates the production of the second messenger cyclic guanosine monophosphate (cGMP), playing roles in homeostasis regulation, maintenance of intestinal barrier function, and anti-inflammatory activity. GUCY2C is primarily associated with intestinal disorders, including functional gastrointestinal diseases (e.g., irritable bowel syndrome and constipation), inflammatory bowel diseases (e.g., Crohn’s disease and ulcerative colitis), and gastrointestinal cancers. Research suggests that activating mutations in GUCY2C can alter the intestinal environment, leading to changes in gut microbiota and increased susceptibility to Crohn’s disease. Additionally, GUCY2C has been linked to congenital sodium-losing diarrhea, with familial GUCY2C diarrhea syndrome potentially progressing to inflammatory bowel disease in adulthood. In neurological disorders, GUCY2C is selectively expressed on midbrain dopaminergic neurons, uniquely regulating attention and motor activity in animals.
In gastrointestinal tumors, GUCY2C exhibits a high positive expression rate in the peripheral blood of colorectal cancer patients, suggesting its potential as an early detection marker for postoperative recurrence and metastasis. Studies show that GUCY2C is highly expressed in gastric mucosal intestinal metaplasia, dysplasia, and gastric cancer. GUCY2C is a relatively specific marker for distinguishing primary from metastatic ovarian mucinous tumors. Numerous studies indicate that GUCY2C often displays abnormal expression in early stages of colorectal carcinogenesis. In metastatic colorectal cancer cells, GUCY2C is specifically overexpressed, highlighting its significant potential as a molecular biomarker for colorectal cancer. FITC-labeled GUCY2C Fc chimera protein can be used to detect GUCY2C expression and distribution in tumor tissues, providing quantitative data for target validation.
GUCY2C is a unique protein receptor localized on the cell membrane, with its core advantage lying in its spatially restricted expression. In normal tissues, GUCY2C is exclusively found on the apical side of intestinal mucosal epithelial cells from the small intestine to the rectum, facing the lumen and rarely interacting with the circulatory system—creating a natural safety barrier for therapy. In cancer tissues, GUCY2C is abundantly and stably expressed across the entire surface of cancer cells in over 95% of colorectal cancers and some gastric and pancreatic cancers. This stark contrast between concealed expression in normal tissues and exposed expression in cancer cells is the fundamental reason GUCY2C is hailed as an ideal therapeutic target, enabling highly selective and low-toxicity precision cancer therapy. GUCY2C on normal cells remains "locked in a safe," minimizing severe off-target toxicity during systemic drug administration, while its exposure on cancer cells provides a clear target for drugs and engineered immune cells.
GUCY2C expression in metastatic cancer cells serves as a biomarker for immunotherapy, including vaccines, CAR-T cells, and immunotoxins. Due to its high expression in colorectal cancer tissues and restricted expression in normal tissues, GUCY2C is an ideal therapeutic target. CAR-T cell therapy targeting GUCY2C is a key direction in colorectal cancer immunotherapy. CAR-T cells expressing chimeric antigen receptors specific to GUCY2C can precisely target and eliminate GUCY2C-expressing tumor cells. Clinical studies demonstrate that GUCY2C-targeted CAR-T cell therapy exhibits favorable safety and efficacy in advanced colorectal cancer patients. Compared to conventional treatments, CAR-T cell therapy offers advantages such as high specificity, potent cytotoxicity, and the ability to generate immune memory. FITC-labeled GUCY2C Fc chimera protein can assess the binding capacity of CAR-T cells to GUCY2C antigen, validating their functional activity.
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed "FITC-Labeled GUCY2C Fc Chimera Protein, Human" (Catalog No.: UA011281), a high-performance fluorescent probe specifically designed for GUCY2C-targeted research and colorectal cancer immunotherapy evaluation. This protein is a fusion chimera of the human GUCY2C extracellular domain and human IgG Fc fragment, labeled with FITC fluorescence. It efficiently binds anti-GUCY2C antibodies or affinity ligands, providing a stable and reliable standardized tool for CAR-T cell therapy evaluation, antibody drug screening, colorectal cancer biomarker research, and other applications.
| Core Advantages | Detailed Parameters / Functional Description |
|---|---|
| High Purity and Intact Bioactivity | Produced using an advanced eukaryotic expression system and highly standardized purification processes, the product undergoes multi-dimensional quality control to ensure >95% purity and correct native conformation (with intact glycosylation). The Fc chimera format enhances protein stability and proper folding. The optimized FITC labeling process ensures high labeling efficiency while maintaining high-affinity binding to antibodies, accurately mimicking the antigenic properties of GUCY2C on colorectal cancer cell surfaces.-- |
| Exceptional Batch Consistency and Stability | Strict management from protein expression and labeling to purification and quality control, combined with a comprehensive release testing system, ensures consistent binding activity, uniform fluorescence intensity, and excellent long-term stability across batches. Provides robust quality assurance for long-term GUCY2C-targeted research.-- |
| Ideal Tool for Multi-Scenario Applications | This protein performs excellently in various applications, including CAR-T cell positivity rate detection by flow cytometry, anti-GUCY2C antibody/antagonist screening, competitive binding assays, colorectal cancer biomarker analysis, and flow cytometry. It is widely applicable to GUCY2C-targeted CAR-T cell therapy development, colorectal cancer diagnostic tool research, and drug activity evaluation.-- |
| Comprehensive Solutions and Professional Support | We provide fully validated standard protocols, representative flow cytometry data, and detailed interpretation guides to help establish stable and reproducible GUCY2C-targeted molecular detection workflows. Nanjing UA-Bio’s technical team offers professional consultation and support for research design, experimental optimization, and data analysis.-- |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or application inquiries regarding "FITC-Labeled GUCY2C Fc Chimera Protein, Human" (Catalog No.: UA011281), please feel free to contact us.
